En Es
Categories

Industry News

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

By Labmedica International staff writers
26 Jan 2021

IllustrationUnder the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment to their long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology products, including instruments and reagents.

In 1999, Sysmex and Roche had entered into a Distributorship Sales and Service Agreement (DSS), under which Roche distributed Sysmex hematology products and provided services in overseas markets. Since then, the demand for hematology testing has evolved, with greater focus on automation of manual processes and streamlining workflow, expanding the utility of hematological parameters so as to support diagnosis, monitoring and treatment across disease areas, beyond routine testing. In 2018, Roche and Sysmex entered into a non-exclusive collaboration agreement to offer Total Laboratory Solutions (TLS). This allows customers who want to purchase products for clinical chemistry, immunochemistry, and hematology testing from one vendor to do so seamlessly with Roche and Sysmex.

The GBP sees the introduction of an IT Solutions Collaboration Agreement. In the newly defined collaboration, the two companies have agreed to utilize their respective IT platforms to improve customer experience, in the short to mid-term, with a longer term ambition to use the IT systems to lead to improved clinical decision making. The GBP agreement will allow Roche and Sysmex to deliver tailored hematology solutions to new and existing customers, while having the benefits of working with a single provider. The partnership will also strive to develop a joint framework to ensure and promote connectivity through standardization of cybersecurity measures. The GBP agreement will run until the end of 2030.

“Roche is committed to supporting improvements in hematology testing, which helps patients with the diagnosis and management of blood diseases, as diverse as anemia and leukemia,” said Thomas Schinecker, CEO Roche Diagnostics. “Extending our longstanding partnership with Sysmex underscores our unique synergy and our objective to offer our customers high-quality hematology solutions to improve the testing efficiency in central laboratories in hospitals and commercial laboratories, ultimately benefiting the millions of patients living with blood disorders.”


Related Links:
Roche
Sysmex




E-mail Print
FaceBook Twitter Google+ Linked in

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests
More info

More articles about Roche Diagnostics

06 Oct 2022
Roche Appoints North American Head Matt Sause as Next CEO of Diagnostics Division
Roche (Basel, Switzerland) has announced that Matt Sause, currently Head of Roche Diagnostics’ North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Read More
28 Mar 2022
Roche and BMS Collaborate on Digital Pathology Algorithms and Cancer Diagnostic Assays
Advances in computation and artificial intelligence (AI) in digital pathology are showing promise to meet the demand for more accurate and comprehensive assessment of pathology results to enable improved patient outcomes. Roche (Basel, Switzerland; www.roche.com) has entered into a collaboration with Bristol Myers Squibb (BMY, New York, NY, USA) to support the advancement of two assays for use in clinical trials with the development and deployment of two new digital pathology algorithms.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
16 Mar 2021
Roche to Acquire Genmark Diagnostics to Access Novel Technology to Test for Pathogens with One Patient Sample
Roche (Basel, Switzerland) and GenMark Diagnostics, Inc. (Carlsbad, CA, USA) have entered into a definitive merger agreement for Roche to fully acquire GenMark which provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample.
Read More
13 Jan 2021
Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer
Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient.
Read More
18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More

Additional news

23 Nov 2022
Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures
The increasing demand for visualization systems for complex surgical procedures, growing demand for minimally invasive surgeries, and rising prevalence of chronic diseases are expected to help the global visualization instruments for minimally invasive surgery (MIS) market register a CAGR of 7.2% between 2022 and 2031 and reach a value of USD 21 billion by 2031.
Read More
11 Nov 2022
Global Diagnostic ECG Market Driven by Increased Incidence of Cardiac Diseases
The rising prevalence of such chronic conditions is necessitating the need for diagnosis and treatment in order to keep track of the patient's daily medical condition and maintain medical records. This, coupled with rising hospitalization of the older population for the treatment of cardiac diseases, has increased the need for electrocardiograph (ECG) diagnosis.
Read More
11 Nov 2022
Radcal to Supply Quality Assurance X-Ray Testing Equipment to West Physics
Radcal Corporation (Monrovia, CA, USA), a leading manufacturer of diagnostic X-ray quality assurance (QA) meters, has reached an agreement with West Physics (Atlanta, GA, USA), one of the largest and most successful Medical Physics groups in the U.S., to supply QA X-ray testing equipment.
Read More
09 Nov 2022
Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.
Read More
08 Nov 2022
Global Infusion Pumps Market Driven by Increasing Incidence of Chronic Diseases
Rising demand for ambulatory infusion pumps in home care, increasing incidence of chronic diseases along with a rapid growth of the geriatric population, and growing number of surgical procedures being performed, are driving the growth of the global infusion pumps market. As a result, the market is projected to register a CAGR of 7% from USD 14.7 billion in 2022 to USD 20.5 billion by 2027.
Read More
07 Nov 2022
Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System
Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.
Read More
07 Nov 2022
AI-Enabled Diagnostic Testing Could Become More Accurate and Reliable than Current Tests
An expanded collaboration between two industry leaders will pave the way for the development of AI-enabled diagnostic testing that is more accurate and reliable than current U.S. tests for patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.
Read More
01 Nov 2022
Global Infectious Respiratory Disease Diagnostics Market Driven by New Multiplex PCR Tests and POC Products
The global infectious respiratory disease diagnostics market size is expected to reach USD 43.6 billion by 2030, driven by an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & non-profit organizations to introduce novel & innovative products to address the growing demand.
Read More
01 Nov 2022
Johnson & Johnson to Acquire Cardiovascular Technology Company Abiomed in USD 16.6 Billion Deal
Johnson & Johnson (New Brunswick, N.J., USA) has entered into a definitive agreement to acquire all outstanding shares of Abiomed, Inc. (Danvers, MA, USA) in a deal valued at approximately USD 16.6 billion which includes cash acquired.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions